Bli medlem
Bli medlem

Du är här

2016-11-14

SciBase: Interim Report

January 1 - September 30, 2016

The third quarter in figures

· Total net sales amounted to TSEK 1,580 (995).
· The loss after tax amounted to TSEK 12,395 (10,260).
· The loss per share amounted to SEK 1.50 (1.24).
· The cash flow from current operations was negative in the amount
of TSEK 10,459 (9,669).

· Significant margin improvement with gross margin increasing to
44.6% in Q3 (17.6%).

The first nine months in figures

· Total net sales amounted to TSEK 4,501 (2,970).
· The loss after tax amounted to TSEK 38,463 (30,378).
· The loss per share amounted to SEK 4.64 (4.71).
· The cash flow from current operations was negative in the amount
of TSEK 34,818 (32,724).

· Significant margin improvement with gross margin increasing to
34.3% (-3.8%).

Important events during the quarter

· A milestone was passed on the German market as the 100th customer
bought and installed a Nevisense device. Our primary market Germany
continues to show good growth with total sales up by 67% and
electrode sales volume up by 118% in the quarter.

· In the period SciBase introduced its new product - Nevisense View
- combining SciBase's patented electrical impedance spectroscopy
(EIS) for early detection of malignant melanoma with visual
information from digital dermoscopy, creating a complete instrument
that improves and simplifies the diagnostic process.

· In the period a new Australian study was presented, which showed
that by using Nevisense, it is possible to reduce the number of cases
that require digital dermoscopy follow-up by almost half. In addition
Nevisense detected most melanoma three months earlier than
traditional methods. The study consisted of 118 patients with 160
lesions, and the results were presented for the first time at the
World Congress on Cancers of the Skin in Vienna on September 1.

· Significant resources allocated during the quarter on the
PMA-process, with continued progress. Ongoing work to provide replies
to feedback from the FDA within several areas. We have passed the
inspection phase and no additional clinical data have been requested
so far.

Important events after the end of the period

· A nominating committee has been appointed for the AGM 2017.

Financial overview

+---------------------------+-----+-----+-----+-----+-------+--------------+
| | | | | |Oct 1 | |
| | | | | |2015 - | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
| |July |Jan 1 |Sep 30 |Jan 1 - Dec 31|
| |1 - |- Sep |2016 | |
| |Sep |30 | | |
| |30 | | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|THE GROUP |2016 |2015 |2016 |2015 |Rolling|2015 |
| | | | | |-12 | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Net sales, SEK ths |1 580|995 |4 501|2 970|5 682 |4 151 |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Gross margin, % |44,6%|17,6%|34,3%|-3,8%|31,0% |2,5% |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Equity/Asset ratio, % |91,3%|94,2%|91,3%|94,2%|91,3% |95,1% |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Net indebtness, multiple |0,09 |0,06 |0,09 |0,06 |0,09 |0,05 |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Cash equivalents, SEK ths |98 |147 |98 |147 |98 272 |133 736 |
| |272 |661 |272 |661 | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Cashflow from operating |-10 |-9 |-34 |-32 |-48 682|-46 588 |
|activities, SEK ths |459 |669 |818 |724 | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Earnings per share (before |-1,50|-1,24|-4,64|-4,71|-5,99 |-6,01 |
|and after dilution), SEK* | | | | | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Shareholder's equity per |12,96|18,93|12,96|24,31|12,96 |21,09 |
|share, SEK* | | | | | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Average number of shares, |8 285|8 285|8 285|6 451|8 285 |6 910 |
|000'* | | | | | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Number of shares at closing|8 285|8 285|8 285|8 285|8 285 |8 285 |
|of period, 000'* | | | | | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Share price at end of |25,20|30,80|25,20|30,80|25,20 |31,00 |
|period, SEK | | | | | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|Average number of employees|22 |15 |21 |14 |18 |14 |
+---------------------------+-----+-----+-----+-----+-------+--------------+
|*Adjusted for in May 2015 | | | | | | |
|performed reversed split, | | | | | | |
|40:1 | | | | | | |
+---------------------------+-----+-----+-----+-----+-------+--------------+

For more information please contact:

Simon Grant, CEO, tele : +46 72 887 43 99

Michael Colérus, CFO, tele : +46 70 341 34 72

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in
Stockholm that has developed a unique point-of-care device for the
accurate detection of malignant melanoma. Its product, Nevisense,
helps doctors to detect malignant melanoma, the most dangerous type
of skin cancer. SciBase was founded by Stig Ollmar, Associate
Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense
is based on substantial research and has achieved excellent results
in the largest clinical study ever conducted on the detection of
malignant melanoma. Nevisense is CE marked in Europe, has TGA
approval in Australia, and is awaiting FDA clearance in the United
States. Nevisense is based on a method called Electrical Impedance
Spectroscopy (EIS), which uses the varying electrical properties of
human tissue to categorize cellular structures and thereby detect
malignancies. SciBase is listed on Nasdaq First North ("SCIB").
Avanza is the certified advisor. Further information is available on
www.scibase.com.

-----------------------------------------------------------
http://news.cision.com/scibase/r/interim-report,c2121572
http://mb.cision.com/Main/12371/2121572/589002.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.